Jean-François Formela, M.D.


Jean-François Formela, co-founder and board member of Korro Bio, is a partner at Atlas Venture and focuses on novel drug discovery approaches and therapeutics. He joined Atlas in 1993 to build the U.S. life sciences franchise.

He is a director and co-founder of IFM Therapeutics, Intellia Therapeutics (NASDAQ: NTLA) and Triplet Therapeutics. Jean-François also serves on the boards of Ikena Oncology (NASDAQ: IKNA) and Scorpion Therapeutics.

Some of his prior investments include Arteaus Therapeutics (acquired by Eli Lilly), CoStim Pharmaceuticals (acquired by Novartis), Exelixis (NASDAQ: EXEL) and Translate Bio (NASDAQ: TBIO, acquired by Sanofi).

Jean-François received his M.D. from Paris University School of Medicine and his MBA from Columbia University.